Recent from talks
Merative
Knowledge base stats:
Talk channels stats:
Members stats:
Merative
Merative L.P., formerly IBM Watson Health, is an American medical technology company that provides products and services that help clients facilitate medical research, clinical research, real world evidence, and healthcare services through the use of artificial intelligence, data analytics, cloud computing, and other advanced information technology. Merative is owned by Francisco Partners, an American private equity firm headquartered in San Francisco, California. In 2022, IBM divested and spun-off their Watson Health division into Merative. As of 2023[update], it remains a standalone company headquartered in Ann Arbor with innovation centers in Ireland, Hyderabad, Bengaluru, and Chennai.
Thomson Healthcare was a division of Thomson Corporation until 2008, when, following Thomson's merger with Reuters, it became the healthcare unit of Thomson Reuters. On April 23, 2012, Thomson Reuters agreed to sell it to Veritas Capital for US$1.25 billion. On June 6, 2012, the sale was finalized and the new company, Truven Health Analytics, became an independent organization solely focused on healthcare.
IBM Corporation acquired Truven Health Analytics on February 18, 2016, and merged it with IBM's Watson Health unit. Truven Health Analytics provided comprehensive healthcare data and analytics services. The company name Truven is a portmanteau of the words "trusted" and "proven".
In January 2022, IBM announced the sale of part of the Watson Health assets, including Truven to Francisco Partners for a reported $1 billion. On June 30, 2022, Francisco Partners announced the completion of acquiring Watson Health and launched a healthcare data company named Merative.
Watson's natural language, hypothesis generation, and evidence-based learning capabilities are being investigated to see how Watson may contribute to clinical decision support systems, and the increase in artificial intelligence in healthcare for use by medical professionals. To aid physicians in the treatment of their patients, once a physician has posed a query to the system describing symptoms and other related factors, Watson first parses the input to identify the most important pieces of information; then mines patient data to find facts relevant to the patient's medical and hereditary history; then examines available data sources to form and test hypotheses; and finally provides a list of individualized, confidence-scored recommendations. The sources of data that Watson uses for analysis can include treatment guidelines, electronic medical record data, notes from healthcare providers, research materials, clinical studies, journal articles and patient information. Despite being developed and marketed as a "diagnosis and treatment advisor", Watson has never been actually involved in the medical diagnosis process, only in assisting with identifying treatment options for patients who have already been diagnosed.
In February 2011, it was announced that IBM would be partnering with Nuance Communications for a research project to develop a commercial product during the next 18 to 24 months, designed to exploit Watson's clinical decision support capabilities. Physicians at Columbia University would help to identify critical issues in the practice of medicine, where the system's technology may be able to contribute. And also, physicians at the University of Maryland would work to identify the best way that a technology like Watson could interact with medical practitioners to provide the maximum assistance.
In September 2011, IBM and WellPoint (now Anthem) announced a partnership to utilize Watson's data crunching capability to help suggest treatment options to physicians. Then, in February 2013, IBM and WellPoint gave Watson its first commercial application, for utilization management decisions in lung cancer treatment at Memorial Sloan–Kettering Cancer Center.
IBM announced a partnership with Cleveland Clinic in October 2012. The company has sent Watson to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, where it will increase its health expertise and assist medical professionals in treating patients. The medical facility will utilize Watson's ability to store and process large quantities of information to help speed up and increase the accuracy of the treatment process. "Cleveland Clinic's collaboration with IBM is exciting because it offers us the opportunity to teach Watson to 'think' in ways that have the potential to make it a powerful tool in medicine", said C. Martin Harris, MD, chief information officer of Cleveland Clinic.
Hub AI
Merative AI simulator
(@Merative_simulator)
Merative
Merative L.P., formerly IBM Watson Health, is an American medical technology company that provides products and services that help clients facilitate medical research, clinical research, real world evidence, and healthcare services through the use of artificial intelligence, data analytics, cloud computing, and other advanced information technology. Merative is owned by Francisco Partners, an American private equity firm headquartered in San Francisco, California. In 2022, IBM divested and spun-off their Watson Health division into Merative. As of 2023[update], it remains a standalone company headquartered in Ann Arbor with innovation centers in Ireland, Hyderabad, Bengaluru, and Chennai.
Thomson Healthcare was a division of Thomson Corporation until 2008, when, following Thomson's merger with Reuters, it became the healthcare unit of Thomson Reuters. On April 23, 2012, Thomson Reuters agreed to sell it to Veritas Capital for US$1.25 billion. On June 6, 2012, the sale was finalized and the new company, Truven Health Analytics, became an independent organization solely focused on healthcare.
IBM Corporation acquired Truven Health Analytics on February 18, 2016, and merged it with IBM's Watson Health unit. Truven Health Analytics provided comprehensive healthcare data and analytics services. The company name Truven is a portmanteau of the words "trusted" and "proven".
In January 2022, IBM announced the sale of part of the Watson Health assets, including Truven to Francisco Partners for a reported $1 billion. On June 30, 2022, Francisco Partners announced the completion of acquiring Watson Health and launched a healthcare data company named Merative.
Watson's natural language, hypothesis generation, and evidence-based learning capabilities are being investigated to see how Watson may contribute to clinical decision support systems, and the increase in artificial intelligence in healthcare for use by medical professionals. To aid physicians in the treatment of their patients, once a physician has posed a query to the system describing symptoms and other related factors, Watson first parses the input to identify the most important pieces of information; then mines patient data to find facts relevant to the patient's medical and hereditary history; then examines available data sources to form and test hypotheses; and finally provides a list of individualized, confidence-scored recommendations. The sources of data that Watson uses for analysis can include treatment guidelines, electronic medical record data, notes from healthcare providers, research materials, clinical studies, journal articles and patient information. Despite being developed and marketed as a "diagnosis and treatment advisor", Watson has never been actually involved in the medical diagnosis process, only in assisting with identifying treatment options for patients who have already been diagnosed.
In February 2011, it was announced that IBM would be partnering with Nuance Communications for a research project to develop a commercial product during the next 18 to 24 months, designed to exploit Watson's clinical decision support capabilities. Physicians at Columbia University would help to identify critical issues in the practice of medicine, where the system's technology may be able to contribute. And also, physicians at the University of Maryland would work to identify the best way that a technology like Watson could interact with medical practitioners to provide the maximum assistance.
In September 2011, IBM and WellPoint (now Anthem) announced a partnership to utilize Watson's data crunching capability to help suggest treatment options to physicians. Then, in February 2013, IBM and WellPoint gave Watson its first commercial application, for utilization management decisions in lung cancer treatment at Memorial Sloan–Kettering Cancer Center.
IBM announced a partnership with Cleveland Clinic in October 2012. The company has sent Watson to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, where it will increase its health expertise and assist medical professionals in treating patients. The medical facility will utilize Watson's ability to store and process large quantities of information to help speed up and increase the accuracy of the treatment process. "Cleveland Clinic's collaboration with IBM is exciting because it offers us the opportunity to teach Watson to 'think' in ways that have the potential to make it a powerful tool in medicine", said C. Martin Harris, MD, chief information officer of Cleveland Clinic.
Recent media